Axel Grothey, MD, on Colon Cancer: Results of the IDEA Collaboration

2017 ASCO Annual Meeting
Tweet this page

Axel Grothey, MD, of the Mayo Clinic Rochester, discusses study findings on shortening the duration of adjuvant oxaliplatin-based therapy, linked to neurotoxicity, for patients with stage III colon cancer. (Abstract LBA1)

Advertisement

Advertisement



Advertisement